Alnylam Pharmaceuticals Ratios and Metrics

Market cap in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2019 - 2015
Period Ending	Dec '25 Dec 5, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2019 - 2015
Market Capitalization	52,026	29,316	21,731	27,358	17,834	12,344	Upgrade
Market Cap Growth	82.32%	34.90%	-20.57%	53.40%	44.47%	7.89%	Upgrade
Enterprise Value	52,068	29,263	21,965	27,663	17,475	11,967	Upgrade
Last Close Price	393.40	225.80	175.80	221.35	149.40	105.76	Upgrade
PS Ratio	19.02	13.50	13.14	28.18	24.02	30.64	Upgrade
PB Ratio	260.98	452.40	-108.87	-184.79	34.48	14.86	Upgrade
P/TBV Ratio	260.98	452.40	-	-	34.48	14.86	Upgrade
P/FCF Ratio	275.76	-	572.67	-	-	-	Upgrade
P/OCF Ratio	229.60	-	230.62	-	-	-	Upgrade
EV/Sales Ratio	18.87	13.48	13.28	28.50	23.54	29.70	Upgrade
EV/FCF Ratio	275.98	-	578.81	-	-	-	Upgrade
Debt / Equity Ratio	11.86	40.89	-12.16	-16.51	3.72	1.57	Upgrade
Debt / FCF Ratio	12.53	-	63.96	-	-	-	Upgrade
Asset Turnover	0.71	0.56	0.50	0.29	0.24	0.17	Upgrade
Inventory Turnover	6.83	3.86	2.85	1.57	1.74	1.19	Upgrade
Quick Ratio	2.37	2.61	2.86	3.17	3.79	4.23	Upgrade
Current Ratio	2.54	2.78	3.08	3.51	4.04	4.47	Upgrade
Return on Equity (ROE)	32.73%	-	-	-526.14%	-106.31%	-69.92%	Upgrade
Return on Assets (ROA)	3.65%	-2.74%	-4.78%	-13.65%	-12.56%	-17.85%	Upgrade
Return on Capital (ROIC)	5.74%	-4.19%	-7.17%	-18.77%	-16.46%	-23.80%	Upgrade
Return on Capital Employed (ROCE)	8.00%	-5.80%	-9.90%	-28.30%	-24.00%	-29.40%	Upgrade
Earnings Yield	0.07%	-0.92%	-1.83%	-3.87%	-4.21%	-5.68%	Upgrade
FCF Yield	0.36%	-0.14%	0.18%	-2.10%	-3.54%	-4.54%	Upgrade
Buyback Yield / Dilution	-4.82%	-2.20%	-2.64%	-2.73%	-3.01%	-5.24%	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.